Moderna, Inc. (MRNA) shareholders
Close on Nov 17, 2026Market cap $82.56BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (14.80%) | 58,929,948 | 14.80% | 13G (passive) amendment | Sep 30, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (13.10%) | 51,803,891 | 13.10% | 13G (passive) amendment | Jun 30, 2026 |
| Stéphane Bancel | 30,384,866 | 7.80% | 13G (passive) amendment | Dec 31, 2023 |
| Vanguard Capital Management | 25,933,824 | 6.53% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 25,301,057 | 6.60% | 13G (passive) amendment | Dec 31, 2023 |
| Capital World Investors | 22,276,996 | 5.60% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MRNA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 51,859,891 | 12.99% | $3.63B | +6,187,867 | 0.16% |
| BlackRock, Inc. | 30,599,409 | 7.66% | $2.14B | +963,533 | 0.03% |
| Vanguard Capital Management LLC | 23,208,792 | 5.81% | $1.63B | +336,334 | 0.03% |
| Capital World Investors | 22,276,996 | 5.58% | $1.56B | +3,579,302 | 0.18% |
| Baillie Gifford & Co | 18,206,778 | 4.56% | $1.28B | −1,779,098 | 1.16% |
| State Street Corp | 15,726,193 | 3.94% | $1.10B | +864,784 | 0.03% |
| Vanguard Portfolio Management LLC | 15,581,313 | 3.90% | $1.09B | −35,054 | 0.05% |
| Geode Capital Management, LLC | 9,710,335 | 2.43% | $678.82M | +275,203 | 0.04% |
| Morgan Stanley | 9,538,094 | 2.39% | $667.95M | +1,066,831 | 0.04% |
| Theleme Partners LLP | 8,057,571 | 2.02% | $564.27M | +9,326 | 33.52% |
| Two Sigma Investments, LP | 7,193,530 | 1.80% | $503.76M | −1,892,874 | 0.36% |
| Invesco Ltd. | 5,780,299 | 1.45% | $404.79M | +995,541 | 0.03% |
| Price T Rowe Associates Inc /Md/ | 5,589,560 | 1.40% | $391.44M | +4,850,982 | 0.04% |
| Charles Schwab Investment Management Inc | 4,838,884 | 1.21% | $338.87M | +104,528 | 0.05% |
| Goldman Sachs Group Inc | 4,671,950 | 1.17% | $327.18M | −1,931,747 | 0.03% |
| Flagship Pioneering Inc. | 4,632,149 | 1.16% | $324.39M | – | 21.07% |
| UBS Group AG | 4,463,211 | 1.12% | $312.56M | +55,304 | 0.04% |
| Bnp Paribas Arbitrage, Snc | 4,377,120 | 1.10% | $306.53M | +59,901 | 0.11% |
| Norges Bank | 3,026,074 | 0.76% | $211.92M | New | 0.02% |
| Northern Trust Corp | 2,985,329 | 0.75% | $209.06M | +33,288 | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 781 | 319M | 79.9% | 147 / 260 | 238 / 83 | 32M | 21M |
| Q1 2026 | 726 | 308M | 77.2% | 148 / 239 | 201 / 84 | 85M | 40M |
| Q4 2025 | 674 | 305M | 76.4% | 112 / 169 | 254 / 69 | 54M | 26M |
| Q3 2025 | 644 | 277M | 69.4% | 68 / 204 | 228 / 90 | 21M | 39M |
| Q2 2025 | 675 | 295M | 73.9% | 92 / 235 | 218 / 104 | 40M | 26M |
| Q1 2025 | 695 | 282M | 70.7% | 88 / 260 | 210 / 127 | 39M | 33M |
| Q4 2024 | 746 | 277M | 69.4% | 145 / 234 | 251 / 170 | 37M | 23M |
| Q3 2024 | 790 | 264M | 66.0% | 63 / 258 | 325 / 218 | 44M | 19M |
| Q2 2024 | 955 | 264M | 66.1% | 128 / 334 | 306 / 64 | 18M | 29M |
| Q1 2024 | 901 | 276M | 69.1% | 111 / 328 | 297 / 82 | 30M | 19M |
| Q4 2023 | 885 | 265M | 66.3% | 141 / 272 | 337 / 134 | 29M | 11M |
| Q3 2023 | 891 | 247M | 61.9% | 82 / 353 | 307 / 143 | 16M | 16M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
584 funds held MRNA in Q2 2026, 42% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MRNA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Growth Fund of America | 14,500,000 | 3.63% | $684.26M | 0.19% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 11,331,692 | 2.84% | $793.56M | 0.03% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 9,154,510 | 2.29% | $641.09M | 0.04% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 8,190,072 | 2.05% | $573.55M | 0.30% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 6,205,997 | 1.55% | $292.86M | 0.30% | May 31, 2026 |
| Fidelity OTC Portfolio | 5,313,300 | 1.33% | $291.28M | 0.68% | Jul 31, 2026 |
| Vanguard Small-Cap Value Index Fund | 5,187,970 | 1.30% | $363.31M | 0.54% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 4,857,193 | 1.22% | $340.15M | 0.04% | Jun 30, 2026 |
| Growth Fund | 4,620,700 | 1.16% | $323.59M | 0.57% | Jun 30, 2026 |
| Vanguard International Growth Fund | 4,584,709 | 1.15% | $216.35M | 0.49% | May 31, 2026 |
| Fidelity 500 Index Fund | 4,450,208 | 1.11% | $210.01M | 0.03% | May 31, 2026 |
| Fidelity Contrafund | 4,335,983 | 1.09% | $303.65M | 0.17% | Jun 30, 2026 |
| Invesco S&P 500 Equal Weight ETF | 4,051,567 | 1.01% | $222.11M | 0.23% | Jul 31, 2026 |
| iShares Biotechnology ETF | 2,574,707 | 0.64% | $180.31M | 1.98% | Jun 30, 2026 |
| Vanguard U.S. Growth Fund | 2,550,076 | 0.64% | $120.34M | 0.25% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Stephane Bancel | Chief Executive Officer, Director | 13,005,140 | 3.26% | Aug 7, 2026 |
| Juan Andres | Chief Operating Officer | 125,000 | 0.03% | Nov 9, 2026 |
| Stephen Hoge | President | 1,792,614 | 0.45% | Oct 16, 2026 |
| James M. Mock | Chief Financial Officer | 60,125 | 0.02% | Oct 7, 2026 |
| Shannon Thyme Klinger | Chief Legal Officer | 87,044 | 0.02% | Sep 8, 2026 |
| Soria Ester Banque | Chief Commercial Officer | – | – | Jul 7, 2026 |
| Michael R. McDonnell | Director | – | – | Jul 10, 2026 |
| Noubar Afeyan | Director | 6,856,164 | 1.72% | May 22, 2026 |
| Abbas Hussain | Director | 12,066 | 0.00% | May 8, 2026 |
| David M. Rubenstein | Director | 9,643 | 0.00% | May 8, 2026 |
| Elizabeth E. Tallett | Director | 4,761 | 0.00% | May 8, 2026 |
| Elizabeth G. Nabel | Director | 19,317 | 0.00% | May 8, 2026 |
| Francois Nader | Director | 32,781 | 0.01% | May 8, 2026 |
| Sandra Horning | Director | 18,585 | 0.00% | May 8, 2026 |
| Paul Sagan | Director | 494,133 | 0.12% | May 1, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Stephen Hoge President | Oct 15, 2026 | Sale(10b5-1 plan) | −39,145 | $220.72 | $8.64M | 1,636,565 |
| Stephen Hoge President | Oct 15, 2026 | Option exercise | +76,452 | $12.21 | $933.48K | 1,675,710 |
| Stephen Hoge President | Oct 14, 2026 | Sale(10b5-1 plan) | −450 | $214.15 | $96.37K | 1,599,258 |
| Stephen Hoge President | Oct 14, 2026 | Sale(10b5-1 plan) | −38,774 | $213.47 | $8.28M | 1,599,708 |
| Stephen Hoge President | Oct 14, 2026 | Option exercise | +76,453 | $12.21 | $933.49K | 1,638,482 |
| James M. Mock Chief Financial Officer | Oct 5, 2026 | Tax withholding | −704 | $190.01 | $133.77K | 60,125 |
| James M. Mock Chief Financial Officer | Oct 5, 2026 | Option exercise | +1,454 | – | – | 60,829 |
| Stephen Hoge President | Sep 15, 2026 | Option exercise | +76,452 | $12.21 | $933.48K | 1,602,310 |
| Stephen Hoge President | Sep 15, 2026 | Sale(10b5-1 plan) | −40,281 | $146.07 | $5.88M | 1,562,029 |
| Stephen Hoge President | Sep 14, 2026 | Option exercise | +76,453 | $12.21 | $933.49K | 1,566,152 |
| Stephen Hoge President | Sep 14, 2026 | Sale(10b5-1 plan) | −40,294 | $144.13 | $5.81M | 1,525,858 |
| James M. Mock Chief Financial Officer | Sep 10, 2026 | Sale(10b5-1 plan) | −19,836 | $134.49 | $2.67M | 74,375 |
| James M. Mock Chief Financial Officer | Sep 10, 2026 | Sale(10b5-1 plan) | −15,000 | $134.49 | $2.02M | 59,375 |
| James M. Mock Chief Financial Officer | Sep 10, 2026 | Option exercise | +19,836 | $30.96 | $614.12K | 94,211 |
| Shannon Thyme Klinger Chief Legal Officer | Sep 4, 2026 | Option exercise | +11,797 | – | – | 87,044 |
| Shannon Thyme Klinger Chief Legal Officer | Sep 4, 2026 | Tax withholding | −5,704 | $148.87 | $849.15K | 81,340 |
| James M. Mock Chief Financial Officer | Sep 4, 2026 | Tax withholding | −5,704 | $148.87 | $849.15K | 74,375 |
| James M. Mock Chief Financial Officer | Sep 4, 2026 | Option exercise | +11,797 | – | – | 80,079 |
| Shannon Thyme Klinger Chief Legal Officer | Sep 1, 2026 | Sale(10b5-1 plan) | −3,471 | $139.95 | $485.77K | 74,129 |
| Shannon Thyme Klinger Chief Legal Officer | Sep 1, 2026 | Option exercise | +3,471 | $30.96 | $107.46K | 77,600 |
| Shannon Thyme Klinger Chief Legal Officer | Sep 1, 2026 | Tax withholding | −1,048 | $140.34 | $147.08K | 75,247 |
| Shannon Thyme Klinger Chief Legal Officer | Sep 1, 2026 | Option exercise | +2,166 | – | – | 76,295 |
| James M. Mock Chief Financial Officer | Sep 1, 2026 | Tax withholding | −1,197 | $140.34 | $167.99K | 68,282 |
| James M. Mock Chief Financial Officer | Sep 1, 2026 | Option exercise | +2,475 | – | – | 69,479 |
| Stephen Hoge President | Sep 1, 2026 | Tax withholding | −4,489 | $140.34 | $629.99K | 1,489,699 |
| Stephen Hoge President | Sep 1, 2026 | Option exercise | +9,283 | – | – | 1,494,188 |
| Shannon Thyme Klinger Chief Legal Officer | Aug 28, 2026 | Option exercise | +329 | – | – | 74,289 |
| Shannon Thyme Klinger Chief Legal Officer | Aug 28, 2026 | Tax withholding | −160 | $142.77 | $22.84K | 74,129 |
| James M. Mock Chief Financial Officer | Aug 28, 2026 | Option exercise | +329 | – | – | 67,164 |
| James M. Mock Chief Financial Officer | Aug 28, 2026 | Tax withholding | −160 | $142.77 | $22.84K | 67,004 |
| Stephen Hoge President | Aug 28, 2026 | Tax withholding | −296 | $142.77 | $42.26K | 1,484,905 |
| Stephen Hoge President | Aug 28, 2026 | Option exercise | +611 | – | – | 1,485,201 |
| Shannon Thyme Klinger Chief Legal Officer | Aug 27, 2026 | Option exercise | +774 | – | – | 74,335 |
| Shannon Thyme Klinger Chief Legal Officer | Aug 27, 2026 | Tax withholding | −375 | $149.66 | $56.12K | 73,960 |
| James M. Mock Chief Financial Officer | Aug 27, 2026 | Option exercise | +774 | – | – | 67,210 |
| James M. Mock Chief Financial Officer | Aug 27, 2026 | Tax withholding | −375 | $149.66 | $56.12K | 66,835 |
| Stephen Hoge President | Aug 27, 2026 | Tax withholding | −695 | $149.66 | $104.01K | 1,484,590 |
| Stephen Hoge President | Aug 27, 2026 | Option exercise | +1,437 | – | – | 1,485,285 |
| Stephane Bancel Chief Executive Officer, Director | Aug 6, 2026 | Option exercise | +252,469 | $19.15 | $4.83M | 6,440,260 |
| Stephane Bancel Chief Executive Officer, Director | Aug 5, 2026 | Sale(10b5-1 plan) | −39,891 | $58.12 | $2.32M | 6,374,835 |
| Stephane Bancel Chief Executive Officer, Director | Aug 5, 2026 | Option exercise | +499,246 | $19.15 | $9.56M | 6,687,037 |
| Stephane Bancel Chief Executive Officer, Director | Aug 5, 2026 | Sale(10b5-1 plan) | −147,473 | $56.21 | $8.29M | 6,539,564 |
| Stephane Bancel Chief Executive Officer, Director | Aug 5, 2026 | Sale(10b5-1 plan) | −187,044 | $58.79 | $11.00M | 6,187,791 |
| Stephane Bancel Chief Executive Officer, Director | Aug 5, 2026 | Sale(10b5-1 plan) | −124,838 | $56.96 | $7.11M | 6,414,726 |
| Stephen Hoge President | Jul 15, 2026 | Option exercise | +16,110 | $19.15 | $308.51K | 1,537,184 |
| Stephen Hoge President | Jul 15, 2026 | Sale(10b5-1 plan) | −53,336 | $67.60 | $3.61M | 1,483,848 |
| Stephen Hoge President | Jul 15, 2026 | Option exercise | +37,226 | $19.15 | $712.88K | 1,521,074 |
| James M. Mock Chief Financial Officer | Jul 2, 2026 | Tax withholding | −703 | $72.50 | $50.97K | 66,436 |
| James M. Mock Chief Financial Officer | Jul 2, 2026 | Option exercise | +1,452 | – | – | 67,139 |
| Stephen Hoge President | Jun 15, 2026 | Sale(10b5-1 plan) | −53,336 | $51.37 | $2.74M | 1,483,848 |
| Stephen Hoge President | Jun 15, 2026 | Option exercise | +37,226 | $19.15 | $712.88K | 1,521,074 |
| Stephen Hoge President | Jun 15, 2026 | Option exercise | +16,110 | $19.15 | $308.51K | 1,537,184 |
| James M. Mock Chief Financial Officer | Jun 5, 2026 | Option exercise | +11,798 | – | – | 71,392 |
| James M. Mock Chief Financial Officer | Jun 5, 2026 | Tax withholding | −5,705 | $51.59 | $294.32K | 65,687 |
| Shannon Thyme Klinger Chief Legal Officer | Jun 5, 2026 | Option exercise | +11,798 | – | – | 79,266 |
| Shannon Thyme Klinger Chief Legal Officer | Jun 5, 2026 | Tax withholding | −5,705 | $51.59 | $294.32K | 73,561 |
| Shannon Thyme Klinger Chief Legal Officer | Jun 4, 2026 | Option exercise | +3,471 | $30.96 | $107.46K | 70,939 |
| Shannon Thyme Klinger Chief Legal Officer | Jun 4, 2026 | Sale(10b5-1 plan) | −3,471 | $50.00 | $173.55K | 67,468 |
| Shannon Thyme Klinger Chief Legal Officer | Jun 1, 2026 | Tax withholding | −1,047 | $47.19 | $49.41K | 67,468 |
| Shannon Thyme Klinger Chief Legal Officer | Jun 1, 2026 | Option exercise | +2,165 | – | – | 68,515 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Moderna's stock actually held short. Settlement fails (shares not delivered on time) peaked at 190,955 shares on Aug 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Stephen Hoge Officer | Oct 15, 2026 | 39,145 | $8.64M | Oct 15, 2026 | Stock Option Exercise |
| Stephen Hoge Officer | Oct 14, 2026 | 39,224 | $8.37M | Oct 14, 2026 | Stock Option Exercise |
| Stephen Hoge Officer | Sep 15, 2026 | 40,281 | $5.88M | Sep 15, 2026 | Stock Option Exercise |
| Stephen Hoge Officer | Sep 14, 2026 | 40,294 | $5.81M | Sep 14, 2026 | Stock Option Exercise |
| James M. Mock Officer | Sep 10, 2026 | 34,836 | $4.69M | Sep 10, 2026 | Restricted Stock Vesting |
| Shannon Thyme Klinger Officer | Sep 1, 2026 | 3,471 | $485.77K | Sep 1, 2026 | Stock Option Exercise |
| Stephane Bancel Officer, Director | Aug 5, 2026 | 499,246 | $28.96M | Aug 5, 2026 | Stock Option Exercise |
| Stephen Hoge Officer | Jul 15, 2026 | 53,336 | $3.61M | Jul 15, 2026 | Stock Option Exercise |
| Paul Sagan Former Director | Jun 18, 2026 | 25,770 | $1.66M | Jun 18, 2026 | Stock Option Exercise |
| Stephen Hoge Officer | Jun 15, 2026 | 53,336 | $2.74M | Jun 15, 2026 | Stock Option Exercise |
| Shannon Thyme Klinger Officer | Jun 4, 2026 | 3,471 | $173.55K | Jun 4, 2026 | Stock Option Exercise |
| Flagship Pioneering, LLC Affiliate | May 21, 2026 | 9,263 | $433.88K | May 21, 2026 | Options Granted - 08/10/2016 |
| Stephen Hoge Officer | May 15, 2026 | 53,336 | $2.58M | May 15, 2026 | Option Granted 08/10/2016 |
| Paul Sagan Former Director | May 8, 2026 | 36,759 | $2.00M | May 8, 2026 | Option Granted - 06/26/2018 |
| Abbas Hussain Director | May 1, 2026 | 5,682 | $264.95K | May 1, 2026 | Restricted Stock Vesting |
Congress trades
29 trades in Moderna reported by 8 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Gilbert Cisneros CA31 | Bought | Oct 20, 2026 | $1K–15K | Nov 10, 2026 |
| Maria Elvira Salazar FL27 | Sold (part) | Sep 24, 2026 | $1K–15K | Oct 7, 2026 |
| Maria Elvira Salazar FL27 | Bought | Aug 19, 2026 | $1K–15K | Sep 9, 2026 |
| Maria Elvira Salazar FL27 | Sold (part) | Aug 19, 2026 | $1K–15K | Sep 9, 2026 |
| Rob Bresnahan PA08 | Sold | Apr 8, 2025 | $1K–15K | May 8, 2025 |
| Rob Bresnahan PA08 | Bought | Feb 25, 2025 | $1K–15K | Mar 27, 2025 |
| Julie Johnson TX32 · joint account | Sold | Jan 15, 2025 | $1K–15K | Feb 12, 2025 |
| Josh Gottheimer NJ05 · joint account | Sold | Feb 1, 2024 | $1K–15K | Mar 7, 2024 |
| Josh Gottheimer NJ05 · joint account | Sold | Sep 15, 2023 | $1K–15K | Oct 15, 2023 |
| Daniel Goldman NY10 | Sold | Jul 12, 2023 | $50K–100K | Aug 13, 2023 |
| Daniel Goldman NY10 | Bought | Apr 10, 2023 | $50K–100K | May 19, 2023 |
| Josh Gottheimer NJ05 · joint account | Bought | Mar 31, 2023 | $1K–15K | Apr 20, 2023 |
| Daniel Goldman NY10 | Sold | Mar 6, 2023 | $50K–100K | Apr 17, 2023 |
| Josh Gottheimer NJ05 · joint account | Sold | Mar 16, 2022 | $1K–15K | Apr 17, 2022 |
| Rohit Khanna CA17 · child | Bought | Feb 14, 2022 | $1K–15K | Mar 8, 2022 |
| Rohit Khanna CA17 · child | Bought | Dec 7, 2021 | $1K–15K | Jan 7, 2022 |
| Josh Gottheimer NJ05 · joint account | Sold (part) | Jul 22, 2021 | $1K–15K | Aug 9, 2021 |
| Josh Gottheimer NJ05 · joint account | Sold (part) | Mar 15, 2021 | $1K–15K | Apr 21, 2021 |
| Marie Newman IL03 | Sold | Jan 29, 2021 | $1K | Apr 21, 2021 82 days late |
| Marie Newman IL03 | Sold | Jan 29, 2021 | $15K | Apr 21, 2021 82 days late |
| Marie Newman IL03 · spouse | Sold | Jan 29, 2021 | $1K–15K | Apr 15, 2021 76 days late |
| Marie Newman IL03 · spouse | Sold | Jan 29, 2021 | $15K | Apr 15, 2021 76 days late |
| Marie Newman IL03 · spouse | Bought | Jan 22, 2021 | $1K–15K | Feb 13, 2021 |
| Marie Newman IL03 · spouse | Sold | Jan 22, 2021 | $1K–15K | Feb 13, 2021 |
| Marie Newman IL03 · spouse | Bought | Jan 14, 2021 | $1K–15K | Feb 13, 2021 |
| Marie Newman IL03 · spouse | Bought | Jan 14, 2021 | $1K–15K | Feb 13, 2021 |
| Marie Newman IL03 · joint account | Sold | Jan 8, 2021 | $1K–15K | Feb 13, 2021 |
| Marie Newman IL03 · spouse | Sold | Jan 8, 2021 | $15K | Feb 13, 2021 |
| Josh Gottheimer NJ05 · joint account | Sold (part) | May 22, 2020 | $1K–15K | Jun 10, 2020 |
See a number that looks wrong?